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Abstract
TBX3 is a member of the T-box family of transcription factors with critical roles in development, oncogenesis, cell fate, and
tissue homeostasis. TBX3 mutations in humans cause complex congenital malformations and Ulnar-mammary syndrome.
Previous investigations into TBX3 function focused on its activity as a transcriptional repressor. We used an unbiased
proteomic approach to identify TBX3 interacting proteins in vivo and discovered that TBX3 interacts with multiple mRNA
splicing factors and RNA metabolic proteins. We discovered that TBX3 regulates alternative splicing in vivo and can promote
or inhibit splicing depending on context and transcript. TBX3 associates with alternatively spliced mRNAs and binds RNA
directly. TBX3 binds RNAs containing TBX binding motifs, and these motifs are required for regulation of splicing. Our study
reveals that TBX3 mutations seen in humans with UMS disrupt its splicing regulatory function. The pleiotropic effects of
TBX3 mutations in humans and mice likely result from disrupting at least two molecular functions of this protein:
transcriptional regulation and pre-mRNA splicing.
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Introduction
TBX3 belongs to the T-box family of transcription factors. The
crucial roles of TBX3 in development are evident in the fact that
heterozygous mutations of TBX3 cause Ulnar–mammary syn-
drome in humans (UMS). This syndrome includes limb malfor-
mations, apocrine and mammary gland hypoplasia, dental and
genital abnormalities. Altered TBX3 expression is implicated in the
pathogenesis of breast and other cancers by affecting cell adhesion,
proliferation and senescence [1,2,3,4,5,6]. Tbx3 improves germ
line competence of iPS cells [7] and can reprogram mature
cardiomyocytes [8]. In addition to its roles in limb and mammary
development, Tbx3 is required for formation and homeostasis of
the cardiac conduction system [9,10] and plays a role in cardiac
development and function in humans [11,12,13,14].
The DNA-binding domain (DBD) that TBX3 shares with other
T-box family members is critical for its function since missense
mutations in this domain cause UMS. In addition to binding
consensus T-box binding elements (TBEs), TBX3 contains a C-
terminal dominant repressor domain [15]. Investigations into
TBX3 molecular functions have focused on transcriptional effects
including repression of p19ARF and p21 to regulate cell
proliferation and prevent apoptosis [3,6,16,17]. Interactions with
histone deacetylases and co-repressors mediate at least some
TBX3 repressor function [5,16,18,19,20]. Beyond these studies,
few direct transcriptional targets or interacting proteins have been
identified.
Given the importance of TBX3 in development, human disease,
and its potential as therapeutic target for cancer and tissue
regeneration, it is essential to define the pathways in which it
functions. To obtain new insights into the molecular functions of
TBX3/Tbx3 (TBX3=human; Tbx3=mouse), we interrogated
interacting partners in vivo. Based on previous studies, we expected
to identify transcription factors and chromatin modifying proteins.
Remarkably, we discovered a novel function of TBX3 with direct
relevance to understanding the molecular mechanisms of muta-
tions that cause human disease.
Results
Mass spectrometry analyses of TBX3 co-
immunoprecipitated proteins identify novel interacting
proteins
We employed unbiased proteomic screens using a custom
polyclonal antibody generated against a peptide from the C-
terminus of TBX3 [21]. We immunoprecipitated (IP’d) protein
lysates from embryonic day (e)10.5 mouse embryos and from the
human embryonic kidney cell line, HEK293 (Figure 1A) to isolate
Tbx3 and TBX3 interacting proteins, respectively. IP’d proteins
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were resolved by SDS-PAGE (Figure 1B, C). Excised protein
bands were subjected to tandem mass spectrometry (MS). We
performed a total of seven IP-MS analyses under the same
experimental conditions on mouse embryos (N= 3) and HEK293
cells (N= 4).
All co-IP’d proteins were identified by detection of multiple
peptides. MS confirmed Tbx3/TBX3 in the IPs (Figure 1D) with a
molecular weight of ,85 kDa. Only proteins present in at least
two independent IP/MS datasets and not in negative control IPs
were considered further: 75 interacting proteins met these criteria
(Table S1). Representative MS traces are shown of hnRNPU,
Raver1, and hnRNPK (Figure 1 E–G). Of the 73 interactors
present in both species, 50 were detected by MS in both mouse
and human co-IPs (Table S1).
TBX3 interacts with RNA binding proteins and splicing
factors in vivo
The known associations of TBX3 with HDACs and transcrip-
tional co-repressors led us anticipate enrichment of such proteins
in our MS screen. To our surprise, ontological classification of
annotated functions, biological processes and functional domains
demonstrated marked enrichment of RNA binding proteins (RNA
BPs) and splicing factors among Tbx3/TBX3 interactors
(Figure 1H, I, Table 1, Table S1). Forty-four percent of interacting
proteins bind RNA (33/75), and many participate in splicing
(Table 1). mRNA processing factors comprise 24% of the
interactome (18/75). 20% contain RNP-1 and/or RRM (RNA
recognition motif) domains (15/75, Figure 1H). Members of the
ribonucleoprotein complex and RNA BPs are more than 30 fold
enriched (Figure 1I) compared to the entire proteome. Over-
representation of RNA BPs is not due to bias from use of antibody
against the TBX3 C-terminus because many interactors were also
co-IP’d with a commercial antibody against an internal epitope
(Table S1, ‘‘SC’’).
To further validate the MS results, we assayed interactions
between endogenous Tbx3/TBX3 and a subset of candidates
detected by MS known to be involved in pre-mRNA splicing and
RNA metabolism. In mouse embryos, Tbx3 co-IP’d with
endogenous Pabp1, Ddx17, hnrnp u, hnrnp k, and Fmr1
(Figure 1 O–R). Endogenous hnRNP C, DDX17, DDX3, hnRNP
U, PABP1 and FMRP co-IP’d with endogenous TBX3 in
HEK293 lysates (Figure 1 S–V, and Figure S1). Thus the
association in vivo between Tbx3/TBX3 and splicing factors is
conserved in mouse and human. We further tested 4 of these
TBX3 binding partners for association with overexpressed, His-
Myc- dually tagged TBX3 in Ni-NTA pull-down assay followed by
anti-myc co-IP (Figure S1, A–E). All 4 interactions tested
withstood both the pull down and the subsequent co-IP.
We then tested whether interactions between TBX3 and a
subset of RNA BPs are RNA dependent in HEK293 cells.
RNAse treatment did not disrupt the interactions between TBX3
and hnRNPC, DDX3 or PABP1, but slightly decreased the
amount of FMRP that co-IP’d with TBX3 (Figure S1, F–G),
indicating that RNA is not absolutely required for the interactions
tested.
DDX3 was the most robust interactor with dually tagged
TBX3 in the Ni-NTA pulldown/co-IP assay, therefore we tested
whether its interaction with TBX3 was direct using purified GST-
DDX3 and MBP-TBX3 fusion proteins (Figure S1K) in a pull-
down assay followed by immunoblotting for TBX3. MBP-TBX3
bound to GST-DDX3, but not GST alone (Figure S1L, lane 3 vs
6).
TBX3 DNA-binding and C-terminal domains mediate
interactions with different RNA BPs
To determine which protein domains of TBX3 mediate its
interactions, we used viral shRNA transduction to knockdown
endogenous TBX3 in HEK293 cells (Figure 2A) and then
transfected various Tbx3 expression constructs (Figure 2B). This
allowed us to test requirements for different Tbx3 functional
domains without simultaneously detecting interactions with
endogenous TBX3. Tbx3+2a contains an additional 20 amino
acids (aas) in the DBD. Point mutations N277D and L143P
identified in humans with UMS abolish DNA-binding activity
[22]. Tbx3DRD1 lacks the C-terminal repressor domain [15]. The
frameshift encoded by the Tbx3 ‘‘ex7 miss’’ missense mutation
substitutes the final 65 aas and generates a 765 aa protein (please
see methods). C-terminal deletions are as shown. All variants are
translated into protein post transfection into HEK293 cells (Figure
S2A), and are efficiently IP’d (Figure S2B, C).
Immunoblot analysis of Tbx3 IP’d proteins with anti-DDX3
demonstrates that DDX3 associates with Tbx3 +/2 exon 2a.
DBD mutations (Figure 2C, lanes 3, 4) abrogate this interaction, as
do C-terminal and RD1 deletions (Figure 2C, lanes 6, 7). Tbx3
lacking a nuclear localization signal (Tbx3DNLS) does not interact
with DDX3 (Figure 2F). The DBD and NLS are required for
Tbx3/hnRNP C interaction (Figure 2D: lanes 3, 4 and 2G), but
C-terminal and RD1 deletions had no effect (Figure 2D, lanes 5–
7). The C-terminus, RD1 and NLS are required for Tbx3/
DDX17 interaction (Figures 2E: lanes 5–7 and 2H), while DBD
mutation had little effect (Figure 2E, lanes 3, 4). We conclude that
nuclear localization of TBX3 is required for the interactors tested
thus far, whereas the C-terminus, RD1 and DBD are independent
and variably required to mediate interactions between Tbx3 and
different RNA BPs. Combined with the RNAse data, our results
indicate that no one ‘‘rule’’ constrains the interaction of TBX3
with its binding partners.
Tbx3 regulates alternative splicing in vitro and in vivo
Given the overrepresentation of splicing factors among Tbx3
interactors, we tested whether Tbx3 regulates splicing using the
Author Summary
TBX3 is a protein with essential roles in development and
tissue homeostasis, and is implicated in cancer pathogen-
esis. TBX3 mutations in humans cause a complex of birth
defects called Ulnar-mammary syndrome (UMS). Despite
the importance of TBX3 and decades of investigation, few
TBX3 partner proteins have been identified and little is
known about how it functions in cells. Unlike previous
investigations focused on TBX3 as DNA binding factor that
represses transcription, we took an unbiased approach to
identify TBX3 partner proteins in mouse embryos and
human cells. We discovered that TBX3 interacts with RNA
binding proteins and binds mRNAs to regulate how they
are spliced. The different mutations seen in human UMS
patients produce mutant proteins that interact with
different partners and have different splicing activities.
TBX3 promotes or inhibits splicing depending on cellular
context, its partner proteins, and the target mRNA.
Eukaryotic cells have many more proteins than genes:
alternative splicing is critical to generate the different
mRNAs needed for production of the specific and vast
repertoire of proteins a cell produces. Our finding that
TBX3 regulates this process provides fundamental new
insights into how altered quantity and molecular function
of TBX3 contribute to human developmental disorders and
cancer.
TBX3 Regulates Splicing
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pRHCglo minigene developed by Singh and Cooper: in CosM6
cells, they showed that the second exon regulates splicing of the
pre-mRNA transcribed from this minigene [23]. We first tested
whether the pRHCglo pre-mRNA was spliced in HEK293 cells
(‘‘Control vector’’, Figure 3A, lane 2) by transfecting the plasmid
into the cells and assaying for transcription/splicing products
produced from the minigene using reverse transcription-PCR
(RT-PCR). We detected the complements of two mRNAs and
sequencing revealed that the 1700 bp cDNA is the RT product of
the unspliced pre-mRNA, while the 190 bp cDNA is produced
from the completely spliced transcript, as shown schematically in
Figure 3A.
Splicing of transcripts from the control vector pRHCglo was not
affected by overexpression of Tbx3 (Figure 3A, lane 4) or by
knockdown of endogenous TBX3 (Figure 3D, lane 4). We replaced
the second exon of pRHCglo (32 bp, shown by Singh and Cooper
to regulate splicing) with a T-box DNA binding element (TBE,
31 bp) to generate the ‘‘T-box vector’’ splicing reporter and again
detected two splicing products by RT-PCR (Figure 3A: lanes 5–6).
We then examined effects of Tbx3 mutations on splicing of the T-
box vector pre-mRNA. Relative to baseline (‘‘b’’, Figure 3B, lane
1), Tbx3 and Tbx3+2a inhibit splicing (Figure 3B, lanes 2, 3), and
this requires the TBE (Figure 3A, lane 4 vs. 3B, lane 2). Consistent
with the domain requirements for interactions, DRD1, exon7
missense mutation, or C-terminal deletions prevented Tbx3
splicing inhibition (Figure 3B: lanes 4–8). Indeed, all detected
reporter mRNA is fully spliced in the presence of C-terminal
mutants that lack the repressor domain, revealing a dominant
effect over the factor(s) that inhibit splicing at baseline. This
suggests that binding of N-terminal portions of mutant proteins to
Figure 1. Splicing factors and RNA BPs are over-represented in the Tbx3 interactome identified by MS and are validated co-
immunoprecipitation. A) Immunoblot (IB) detecting endogenous TBX3/Tbx3 protein immunoprecipitated (IP) from HEK293 and mouse embryo
lysates, respectively. black arrowhead: IgG. B, C) Representative, Coomassie (B, 4–12% gradient) and Oriole stained (C, 10%) SDS-PAGE gels of anti-
Tbx3 or negative control IgG IP’d complexes subsequently analyzed by MS. Red arrowheads, TBX3/Tbx3. D–G) Representative mass spectra for
identification of Tbx3 (D) and interacting proteins: Hnrnp U (E), Raver 1 (F), Hnrnp K (G). Diagnostic b- and y-series ions are shown in red and blue. H)
Gene ontology (GO) analysis identified predominant molecular functions and biological processes of Tbx3 interacting proteins. Diagram shows
percent interacting proteins annotated with each GO term (molecular function, MF; biological process, BP; cellular component, CC; functional domain
(Interpro and Prosite) and molecular pathway (KEGG). I) Bar graph of number of proteins and fold enrichment per category. J–V) Mouse embryo and
HEK293 lysates were immunoprecipitated with the antibody listed at the top of the panels (IP) and the antibodies used to probe the immunoblot (IB)
below. J–N) Immunoprecipitation of endogenous: pabp1, Ddx17, hnrnp k, Fmr1, hnrnp u from e10.5 mouse embryo lysates. red arrowheads:
interacting protein; black arrowheads: IgG O–R) Endogenous Tbx3 coIPs with pabp1 (O), Ddx17 (P), hnrnp k and hnrnp u (Q), Fmr1 (R) in e10.5 mouse
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the TBE in the T-box vector DNA (or nascent transcript) disrupts
the function of factors that normally inhibit splicing. This effect is
dependent on the TBE because these mutant proteins had no
effect on splicing of the Control vector (Figure 3E). Baseline
splicing was observed with the L143P, N277D and Tbx3DNLS
mutants (Figure 3B, lanes, 10–12). Knockdown of endogenous
TBX3 regulates the ratio of unspliced/spliced T-box vector
mRNA (Figure 3C) such that only fully spliced mRNA is present
(Figure 3B, lane 15). In combination with the observation that
knockdown of endogenous TBX3 has no influence on splicing of
the Control vector pre-mRNA (no TBE, Figure 3D), we conclude
that endogenous TBX3 inhibits splicing of T-box vector pre-
mRNA via the TBE.
The in vitro splicing results led us to test whether Tbx3 regulates
splicing in vivo. We conditionally ablated Tbx3 function in e10.5
mouse embryo forelimb mesenchyme using Prx1Cre [24] and
assayed for differential splicing using mRNA sequencing (RNA-
Seq). We microdissected control and Tbx3;Prx1Cre mutant
forelimb buds into anterior and posterior segments, made cDNA
libraries from the mRNA obtained (2 from each geno/tissue type)
and performed deep sequencing Messenger RNAs with
annotated alternate splice forms (UCSC knownAlt [25]) were
evaluated for differential exon usage events between WT and
Tbx3 ablated samples based on RPKM values. The following
criteria were used to identify statistically significant alternative
splicing events: Fisher’s exact test p,=0.05, Bayesian error rate
,=0.1, fold change .=1.5, reads supporting event .=15
(please see Supplemental Information for complete informatics
methodology).
We randomly selected 11 of the statistically significant exon
alternative splicing (AS) events identified in silico in the anterior
mesenchyme (Tables S2 and S3) for validation by RT-PCR
(Figure 4A–F9, Figures S3 and S4A). All statistically significant
events tested validated, whereas most events tested that were
below the false discovery rate of 5% did not (Tables S2, S3, Figure
S4A, B). RNA-Seq reads visualized with the Integrated Genome
Viewer (IGV) show that remarkably, Tbx3 has opposite effects
on Dlg3 splicing in the anterior and posterior limb: in the anterior
limb bud Tbx3 promotes inclusion of exons 8 and 9 (Figure 4A,
C9: loss of Tbx3 results in increased levels of the short isoform)
whereas in the posterior, Tbx3 promotes exon skipping (Figure 4B–
C9). Similar findings occurred with Nfkb1 exon 11 (Figure 4D–F9).
Additional examples of Tbx3 variably promoting inclusion
or skipping are shown in Figure S3. These experiments reveal
that Tbx3 influences AS in a transcript- and tissue-specific manner
in vivo.
Since altered splicing after ablation of Tbx3 could be indirect
or secondary to transcriptional effects, we tested whether Tbx3
directly regulates splicing of the in vivo target Nfkb1. We replaced
exon 2 of pRHCglo with Nfkb1 exon 11 (92 bp) flanked by
3 different fragments from the adjacent introns (Figure 4G).
Primary sequences of these fragments contained the number
of TBE cores (GGTG or CACC, please see Supplemental
Methods in Text S1 for sequence of each fragment) predicted
by chance. However, a motif located 4 bps from the splice
donor site of exon 10 was in the larger context of a TBE consensus
motif (59 A/TGGTGTG) [26]. Remarkably, the only difference
between Fragment 2 and Fragment 3 was the addition of
15 bps containing this consensus motif, and only Nfkb1 minigene
Fragment 3 (Nfkb1 F3) was alternately spliced in response to
TBX3 knockdown, which resulted in Nfkb1 minigene exon 11
skipping and inclusion (Figure 4H, lane 12), as observed in vivo
(Figure 4F9). Figure 4I schematically shows splice variants
(sequence confirmed) resulting from TBX3 knockdown. This is
consistent with the T-box vector minigene experiments which
showed that TBX3 requires a TBE to regulate splicing (Figure 3A,
Table 1. TBX3 interacting proteins involved in mRNA splicing.
NAME UNIPROT ANNOTATION SOURCE *
Heterogeneous nuclear ribonucleoprotein A1-like 2 Q32P51 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein A1-like 3 P09651 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein A2/B1 P22626 Spliceosome mRNA splicing GO, UP
Heterogeneous nuclear ribonucleoprotein A3 P51991 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein C (C1/C2) P07910 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein H1 P31943 Spliceosome mRNA splicing GO, UP
Heterogeneous nuclear ribonucleoprotein K P61978 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein M P52272 Spliceosome mRNA splicing GO, KEGG, UP
Heterogeneous nuclear ribonucleoprotein U Q00839 Spliceosome mRNA splicing GO, KEGG, UP
Poly(A) binding protein, cytoplasmic 1 P11940 Spliceosome mRNA splicing GO, UP
Heat shock 70 kDa protein 1-like P34931 Spliceosome KEGG
Heat shock 70 kDa protein 1A; heat shock 70 kDa protein 1B P08107 Spliceosome KEGG
Heat shock 70 kDa protein 2 P54652 Spliceosome KEGG
Heat shock 70 kDa protein 8 P11142 Spliceosome Alt splicing KEGG, UP
Poly(rC) binding protein 1 Q15365 Spliceosome KEGG
ATP-dependent RNA helicase DDX5 P17844 Spliceosome mRNA splicing GO, KEGG, UP
Probable ATP-dependent RNA helicase DDX17 Q92841 RNA binding Alt splicing GO, UP
ATP-dependent RNA helicase DDX3X O00571 RNA binding GO, UP
Ribonucleoprotein PTB-binding 1 Q8IY67 RNA binding Alt splicing GO, UP
* GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; UP: Uniprot.
doi:10.1371/journal.pgen.1004247.t001
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B). Deletion/mutation of TBX3 C-terminal domains previously
demonstrated to be required for TBX3 interactions have the same
effect on Nfkb1 minigene splicing as TBX3 knockdown (Figure 4J,
lanes 3–6).
TBX3 associates directly with alternately spliced and TBE -
containing RNAs
Splicing complexes are recruited to the exon-intron and/or
exon-exon junctions on pre-mRNAs. TBX3’s effects on splicing
and the RNA–independence of interactions with RNA BPs/
splicing factors (Figure S1A) suggest physical association of TBX3
and mRNAs in vivo. To test this, we performed RNA immuno-
precipitation (RIP) and RT-PCR. Anti-Tbx3 RIP on mouse
embryo mRNA/protein showed that Pus10, Nfkb1, Brca1, and Dlg3
transcripts were associated with Tbx3 (Figure 5A, lanes 5), while
the negative controls mRNAs H2a, Ccne and p21 (Figure 5A9) were
not. Endogenous TBX3 RIP’d PUS10 and NFKB1 mRNAs in
HEK293 cells as well (Figure 5B), but not BRCA1 or DLG3, which
further supports the conclusion that Tbx3/TBX3 regulation of
splicing is transcript and context dependent.
These surprising results led us to determine if TBX3 associates
directly with RNA. TBX3 could influence splicing of the T-box
vector minigene (Figure 3) or Nkb1 (Figure 4) by binding to the
TBE in the reporter or genomic DNA in a cotranscriptional
processing mechanism, or by binding to the pre-mRNAs. We
generated an MS2-TBX3 fusion protein in which the MS2 RNA
binding protein domain was fused in frame at the N-terminus of
TBX3 (MS2-TBX3). We replaced exon 2 of pRHCglo with
multimeric MS2 binding sites (‘‘MS2-Vector). Note that the MS2
binding site only forms in RNA [27]. The MS2-vector is fully
spliced in HEK293 cells to a form that contains only exons 1 and 3
(190 bp, Figure 5C, D lane 1). In the presence of MS2-TBX3, a
partially spliced mRNA is present consisting of exons 1–3, but no
introns (928 bp, Figure 5C, D lanes 3,5). This splice variant was
not present when either MS2-GFP or wild type TBX3 were
employed (Figure 5D, lanes 4 and 6 respectively). These results
indicate that MS2-TBX3 regulates splicing of the reporter by
binding the MS2 binding site in the mRNA. Furthermore,
complete splicing inhibition seen with the T-box vector (Figure 3B)
was not observed for the MS2-vector transcript, consistent with
our other results indicating that the effects of TBX3 on splicing are
transcript dependent.
To probe the mechanism whereby Tbx3 interactions with RNA
BPs and RNA influence splicing, we tested whether interacting
proteins also bind the Nfkb1 mRNA in mouse embryonic tissue. Of
the 6 interactors tested (Figure 6A), only hnrnpk did not bind this
mRNA. As with Tbx3, binding of these interactors to Nfkb1
mRNA is specific as they do not bind gapdh or actin mRNAs
(Figure 6A). We next tested whether Tbx3 was required for Nfkb1
binding by Ddx3 and hnrnpu (the most robust Nfkb1 binders) by
assaying mRNA/protein complexes in tissues from wild type and
Tbx3 null embryos. Loss of Tbx3 abolished the interaction
between Ddx3 and Nfkb1 mRNA, but not hnrnpu (Figure 6B).
Additionally, knockdown of Ddx3, but not hnrnpu, had the same
effect on Nfkb1 splicing as knockdown of Tbx3 (Figure 6C). These
results indicate that Tbx3 functions to recruit and/or dock some
interactors to mRNAs that are alternately spliced in a Tbx3-
responsive manner.
To further examine the interaction of TBX3 directly with RNA,
we performed EMSAs with RNA probes and purified TBX3
protein. Of 14 variably complex RNA probes tested, TBX3 bound
poly-GGU, -AG, -GU RNAs (Figure S5A–C), see Supplemental
Information in the file Text S1 for all probes tested). It also bound
strongly to a probe containing two RNA-TBEs 59UGGUGU
(Figure 7A), but not to a probe with mutated TBEs (Figure 7B)
Further, we examined TBX3 binding to RNAs from Nfkb1 F1-3
(previously assayed in the minigene, Figure 4I, J). The F1-derived
probe was not bound despite the presence of a 59UGGUGU motif
(Figure 7C). Although F2 was not sufficient to drive minigene
splicing, TBX3 bound this fragment, as well as A consensus TBE
present in F3 (Figure 7D,E). Mutation of the TBEs in F2 and F3
disrupted binding by TBX3 (Figure S5, panel F). In combination
with the Nfkb1 minigene splicing findings, these results reveal that
TBE context is critical for both RNA binding and splicing
regulation.
We next tested whether endogenous TBX3 in HEK293 cells
binds RNA. Lysates were incubated with radiolabeled RNA probe
+/2 anti-TBX3 antibody and +/2 TBX3 knockdown. Probe
containing 2 RNA-TBEs (59 UGGUGU) was shifted by proteins in
wildtype lysate (Figure 7F, lane 5, blue arrowhead) and super-
shifted by anti-TBX3 antibody (Figure 7F, lanes 2, 3, red
arrowhead). Negative control antibody does not supershift these
complexes (Figure S5G, lane 6). In TBX3 knockdown lysate, a
different complex was detected (Figure 7F, lane 6, gray
arrowhead). Mutation of the RNA to 59UCCUGU resulted in
shifted probe/protein complexes that were insensitive to anti-
TBX3 antibody or loss of TBX3 (Figure 7G lanes 2, 3, 5, gray
arrowheads). Similar experiments with the RNA motif from Nkb1
F3 revealed a complex (Figure 7H lane 5; blue arrowhead) that
was supershifted by anti-TBX3 antibody (Figure 7H, lanes 2, 3;
red arrowhead) and lost with TBX3 knockdown (Figure 7H, lane
6). The supershift did not occur with negative control antibody
(Figure S5H, lane 6). Collectively, these data indicate that TBX3
binds RNA containing RNA-TBEs and in the absence of TBX3,
other protein(s) bind these RNAs.
We defined putative TBEs conservatively based on the literature
[26,28]: 59 T/A GGTG T/A/G. Among the 11 statistically
significant alternatively spliced genes in the anterior limb
compartment that we validated, this TBE is present in the introns
flanking the alternatively spliced exons of Nfkb1, Dlg3, Ttc3, Pus10,
Brca1, Fanca, Cacnb3, Arnt2, Wdr70 (9/11, Table S4). Not all of
these sites were conserved, although for some sites, there was
conservation to opossum and deeper.
MEME motif analysis of 1 kb of sequence flanking statistically
significant alternatively spliced exons from the anterior RNA-Seq
dataset (Table S3) revealed that SINE motifs containing TBEs
were highly overrepresented (Figure 7I, J, Table S4). The MEME
motifs shown were present in 20 and 10 of 51 statistically
significant alternative splicing events detected with Expect values
of 1.1 e296 and 3.3 e283, respectively. MEME mapping did not
reveal a pattern or consistent location or orientation of these
overrepresented motifs relative to the alternative splicing event
(Table S4). A Tbx3 motif with a less stringent core (59 G/T G/C
TG N) was identified by MEME on Tbx3 ChIP-Seq data from
adult mouse heart [28]. This sequence (as well as 59 T/A GGTG
T/A/G) is present within the larger MEME motifs we identified
(Figure 7 I, J). Among the 11 AS genes we validated, these MEME
motifs are present in Dlg3, Dtnb1, Pus10, Brca1, Fanca1. Table S4
shows location and conservation of putative TBEs and MEME
motifs for all 11 validated alternative splicing events in the anterior
compartment. In total, the data indicate that splicing outcomes are
affected by binding motifs present near alternatively spliced exons,
but the splicing outcomes are context and transcript dependent.
Discussion
We used a rigorous series of biologic replicates, controls and
statistical filters to identify TBX3 interacting proteins in HEK293
TBX3 Regulates Splicing
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cells (75 interactors) and E10.5 mouse embryos (59 interactors) by
mass spectrometry. This unbiased proteomic screen revealed that
TBX3/Tbx3 interacts with RNA BPs and splicing factors. Our
discovery that TBX3 regulates alternative splicing in vivo suggests
new mechanisms of TBX3–mediated regulation of target genes.
Importantly, TBX3 proteins that model different human UMS
mutations have different splicing activities: C-terminal mutants
dominantly interfere with splicing inhibition mediated by endog-
enous TBX3, while DNA binding and NLS mutants neither
inhibit splicing nor have dominant effects.
Tbx3 physically associates with mRNAs that undergo AS in
response to Tbx3 loss of function in vivo, and directly binds RNA
containing the core motif of T-box DNA-binding elements
(RNA-TBEs). Since AS is a critical mechanism of post- and co-
transcriptional gene regulation and proteome diversity and
disruption of AS occurs in many cancers [29,30,31], the finding
that TBX3 regulates this process provides new insights into how
altered dosage and molecular functions of TBX3 contribute to
human developmental disorders and cancer. For example, the
mechanism(s) of repression of CDKN2A, which is alternatively
spliced to produce the p16INK4 and p14ARF tumor suppressors,
will need to be reexamined for potential post-transcriptional effects
of TBX3.
Interactions between TBX3 and specific RNA-binding proteins
require different TBX3 functional domains indicating that
crosstalk with different molecular partners mediates distinct
TBX3 functions. We tested the effect of NLS deletion on 3
Tbx3 interactors: DDX3, hnRNPC and DDX17, and the data
suggest that these specific interactions take place within the
nucleus. Unlike wild type Tbx3, the Tbx3 NLS mutant does not
inhibit splicing, nor does it have the dominant effect on splicing
seen with most C-terminal mutants (which still get to the nucleus,
Moon unpublished and [15]). These findings are consistent with
the overwhelming evidence that for the majority of mRNAs,
splicing is a co-transcriptional event [32]. Many of the Tbx3
interacting proteins we identified (DDxs, hnRNPs, Fmr1 and
others) are known to be present in both the nucleus and the
cytoplasm. Wild type Tbx3 is also present in the cytoplasm
[21,33], thus it is likely that Tbx3 interacts with some partners
outside the nucleus. DDX3, DD17, hnRNPc1, hnRNPU have all
been previously reported to play role in splicing by directly
binding to RNA or via the splicing complex; a major shift has
occurred in the field due to the discovery that the majority of
splicing is cotranscriptional and nuclear, thus some functions of
these proteins previously attributed to the cytoplasm are nuclear.
Our study reveals novel properties of these proteins in terms of
their interaction with TBX3 and that in some cases, the ability of
the RNA BP to influence splicing is TBX3-dependent. For
example, although DDX3 has previously been shown to regulate
splicing, we have discovered a novel DDX3 splicing target pre-
mRNA (Nfkb1) and shown that DDX3 requires TBX3 to bind
this target. Future studies of the functional consequences of
interactions with TBX3 may reveal completely novel functions
for some of its partners.
Figure 2. Different Tbx3 protein domains are required for protein-protein interactions. Stable retroviral mediated knockdown of
endogenous TBX3 in HEK293 cells followed by transfection of wild type and Tbx3 mutant proteins as diagrammed. Lysate IPs were assayed by IB with
antibodies noted at bottom of panels. A) Immunoblot of control versus TBX3 shRNA (KD) lysates. B) Schematic of Tbx3 mutant proteins. Confirmation
of expression and successful IP of overexpressed Tbx3 proteins is presented in Figure S2. C–E) Interactions of mutant Tbx3 proteins with DDX3,
hnRNP C, and DDX17 tested by IP and western blotting. F–H) Tbx3 NLS is required for Tbx3 interactions with DDX3, DDX17 and hnRNP C. red
arrowheads: interacting proteins; black arrowheads: IgG.
doi:10.1371/journal.pgen.1004247.g002
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Although we have discussed the TBX3 DBD as such, TBX3
complexes with AS RNAs in vivo and directly binds RNAs
containing TBEs. The Nfkb1 minigene and EMSA results reveal
that the context of RNA-TBEs is critical for TBX3 to affect
splicing. TBE motifs are over-represented in sequences flanking
alternative exon events resulting from loss of Tbx3 in vivo
contain, including SINE motifs. This is noteworthy because
evidence for crucial regulatory functions of SINEs is accumulat-
ing [34]. MEME mapping of sequences flanking statistically
significant AS events did not reveal a pattern or consistent
location of putative TBEs or other overrepresented motifs
relative to the splicing event. The results with Dlg3 and Nfkb1
in vivo and the Nfkb1 minigene are very informative in this regard:
these transcripts are alternatively spliced, and putative TBEs or
MEME motifs are near the alternatively spliced exons. However,
loss of Tbx3 has the opposite effect on splicing of these
transcripts in the anterior and posterior compartments of the
limb (Figure 4 A–F9): Tbx3 promotes exon inclusion of Dlg3
exons 8/9 and of Nfkb1 exon 11 in the anterior, but exclusion of
these exons in the posterior. Furthermore, inclusion of putative
TBEs from different regions flanking Nfkb1 exon 11 have
different effects on splicing of the Nfkb1 minigene (Figure 4G,
H). Additional evidence of context dependence is the finding that
Tbx3 and TBX3 both bind Nfkb1 and Pus10 mRNAs in vivo (in
mouse embryo and HEK293 cells, respectively) but only Tbx3
binds Dlg3 and Brca mRNAs. We conclude that alternative
splicing outcomes are affected by binding motifs present near
affected exons, but the outcomes are context and transcript
dependent; future studies will test our postulate that this is due to
interaction with different cofactors.
Splicing and transcription are most often coupled [32]:
chromatin-associated factors aid in the recruitment of the splicing
complex to nascent pre-mRNAs and regulate exon inclusion or
exclusion [35]. HDAC inhibition disrupts AS of hundreds of pre-
mRNAs [36]. Our screen identified TBX3 interactions with
chromatin structural/modifiying factors H2A, H2B1B, TCP1 and
PTB1. HDACs 1–5 also interact with TBX3 [5]. Our observation
that, at least for the Nfkb1 mRNA, TBX3 regulates AS by directly
binding to an intronic RNA-TBE raises the issue of whether the
effect of TBX3 on splicing are co-transcriptional and could also be
mediated by TBX3 binding to TBEs in genomic DNA. We
examined the published Tbx3 ChIP-Seq dataset [32] but did not
find ChIP peaks within the 10 kb flanking the AS exons of any of
the 11 validated genes. However, this ChIP-Seq was performed on
adult mouse heart after forced pan-myocardial expression of
Tbx3, whereas our RNA-Seq and splicing assays were on
embryonic mouse limb. Additional studies to determine whether
TBX3 influences splicing and gene expression by effects on
chromatin and/or by binding DNA and RNA TBEs in
alternatively spliced targets are underway.
Figure 3. Tbx3 regulates alternative splicing in vitro. A) Either pRHCglo (Control vector) or RHCGlo+T-box binding element (T-box vector) were
co-transfected into HEK293 cells with Tbx3 expression vectors indicated above each lane. Splicing products were assayed by RT-PCR; positions of
unspliced pre-mRNA and spliced products are indicated at left. Hprt control PCR products are shown below. B) Ability of Tbx3 mutant proteins to
regulate T-box vector splicing. Symbols at bottom of panel summarize effect on splicing inhibition. b, baseline ratio of pre-mRNA to completely
spliced mRNA; +, splicing inhibited over baseline; 2, no inhibition. C) Immunoblot of control or TBX3 siRNA lysates probed for TBX3 and tubulin. D)
Splicing products from the control minigene vector in the presence of Tbx3 or Tbx3 knockdown, assayed by RT-PCR. Schematics and positions of
unspliced pre-mRNA (1746) and fully spliced (190) products are indicated at left. Baseline (b) ratio of unspliced to fully spliced mRNA from the control
minigene vector is unchanged by overexpression of Tbx3 or knockdown of endogenous TBX3 in HEK293 cells. E) Splicing products from the control
minigene vector in the presence of Tbx3 mutant proteins assayed by RT-PCR. In the absence of a TBE in the minigene, Tbx3 mutant proteins have no
effect on the baseline ratio of unspliced to fully spliced mRNA.
doi:10.1371/journal.pgen.1004247.g003
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We focused the present study on the splicing function of TBX3
with respect to novel binding partners however, it is unlikely that
all interactions between TBX3 and RNA-binding partner proteins
are related to splicing regulation: many of these interactors are
known to have multiple roles and influence trafficking and other
aspects of mRNA processing, and some have transcriptional effects
and DNA binding properties. The numerous hnRNPs that
interact with Tbx3 exemplify this point. This diverse family of
multifunctional proteins has crucial roles in RNA processing in
addition to AS. Dysregulation of hnRNP function and resulting
disruption of AS contribute to carcinogenesis [37,38]. Among the
12 hnRNP TBX3 interactors (Table 1), interactions with hnRNP
U and hnRNP A1 could have widespread consequences: depletion
of hnRNP U has profound effects on AS by regulating the
maturation of the U2 snRNP and all snRNAs required for splicing
[39,40]. More AS events are altered by depletion of hnRNP A1
Figure 4. Tbx3 regulates alternative splicing in vivo. A, B, D, E) Screen shots from the Integrated Genome Viewer (IGV) comparing RNA-Seq
reads obtained from wild type/control anterior (CA1, CA2) or posterior (or CP1, CP2) limb bud mRNA libraries with those from Tbx3;Prx1Cre mutants
after conditional ablation of Tbx3 in anterior or posterior limb bud mesenchyme (MA1, MA2 or MP1, MP2, respectively). Red arrowheads indicate
positions of exons that are differentially spliced in a Tbx3-dependent manner. A) Loss of Tbx3 causes exclusion of Dlg3 exons 8 and 9 in the mutant
anterior compartment (MA1, MA2 red arrowheads). B) Loss of Tbx3 causes inclusion of Dlg3 exons 8 and 9 in the mutant posterior compartment
(MP1, MP2 red arrowheads). C) Schematic of splice variants and location of PCR primers used to detect different Dlg3 isoforms by RT-PCR assay of
control versus Tbx3mutant mRNAs (C9, Anterior and Posterior compartments, ctl, control; mt, mutant). D) Loss of Tbx3 causes exclusion of Nfkb1 exon
11 in the mutant anterior compartment (MA1, MA2 red arrowheads). E) Loss of Tbx3 causes inclusion of Nfkb1 exon 11 in the mutant posterior
compartment (MP1, MP2 red arrowheads). F) Schematic of splice variants and location of PCR primers used to detect different Nfkb1 isoforms by RT-
PCR assay of control versus Tbx3 mutant mRNAs (F9, Anterior and Posterior compartments, ctl, control; mt, mutant). G) Schematic of Nfkb1 exon 11
minigenes in which exon 2 of pRHCglo was replaced by different Nfkb1 genomic fragments (F1, F2, F3). H) Splicing products assayed by RT-PCR from
the Nfkb1minigenes containing fragments F1, F2 or F3 in the presence of Tbx3 or after knockdown (KD). Only F3 confers differential splicing (lane 12).
I) Schematic of splice variants obtained in vivo (sequence confirmed) in response to TBX3 knockdown. J) Splicing products assayed by RT-PCR from
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and U in human 293T cells than other hnRNPs [40]. Because
hnRNPs exhibit context-dependent effects on splicing and RNA
processing, they may modulate TBX3 target gene activity in a
tissue-specific manner.
The association of TBX3 with several factors that regulate
response to estrogen and other nuclear hormones (Table S1)
[41,42,43,44,45] is interesting in the context of postulated roles for
TBX3 in tumorigenesis and metastasis of hormone responsive
breast, prostate and other cancers. DDX RNA helicases facilitate
alternative promoter usage and splicing, and are transcriptional
co-activators with ERa, p53 and Runx2 [46,47,48,49]. Notably,
TBX3 regulates both p53 activation and Runx2 expression [17,50].
Phb2 coregulates estrogen responsive genes by potentiating the
effects of antiestrogens, inhibiting the effects of estrogens, and
recruiting HDAC1 and 5 (both are Tbx3 interactors [5]) to
nuclear hormone targets [42,51]. XRCC6 interacts with Msx2 (a
known TBX3 interactor) and Runx2 (a TBX3 target) [52] and
mutations in XRCC6 are associated with breast cancer risk and
estrogen exposure [43]. We also detected Capera (Coactivator of
AP1 and Estrogen Receptor) in one co-IP by MS and by yeast 2-
hybrid screen for Tbx3 interactors (Kumar et al., submitted).
Capera modulates steroid hormone receptor-mediated transcrip-
tional regulation and AS [53]. Future studies will address the
functional relevance of interactions between TBX3 and splicing
factors in regulating estrogen response.
A comprehensive discussion of the other classes of TBX3
interactors identified in these analyses awaits validation of
members of each class. However, the presence of multiple
cytosolic and mitochondrial RNA and protein chaperones, nuclear
import/export factors (including previously identified XPO1 [33]),
ribosomal components, and nuclear membrane proteins suggest
additional functions for TBX3 in both the nucleus and cytoplasm.
The diverse interactome of TBX3 suggests that it may function as
a docking molecule for the assembly of various RNA processing or
regulating complexes and could functionally couple post-tran-
scriptional processing and protein translation.
TBX5 was previously shown to interact with SC35 and
regulate splicing [54]. The fact that SC35 was not detected as a
TBX3 interactor by any of our screens suggests that the
interactome of TBX3 and 5 are different, as would be predicted
since there is minimal homology between these proteins outside
the DNA binding domain. Thus, Tbx3 is among an increasing
number of transcription and DNA binding factors that complex
with splicing proteins and future studies to determine if other Tbx
proteins bind RNA and/or influence splicing are warranted
[55,56,57].
Figure 5. Endogenous Tbx3/TBX3 associates with specific mRNAs in mouse embryonic tissues and HEK293 cells. A, A9) RNA-IP with
anti-Tbx3 on embryo lysates in the presence or absence of RNAseA followed by RT-PCR for transcript detection. Tbx3 binds Pus10, Nfkb1, Brca1 and
Dlg3 mRNAs. A9) H2a, Ccne and p21 are negative controls for the positive interactions seen in panel A, as Tbx3 does not bind/RIP these mRNAs. B, B9)
RIP and cross-linked RNA-IP (CLIP) of HEK293 lysates followed by RT-PCR. Endogenous TBX3 binds the PUS10 and NFKb1 mRNAs but not BRCA1, DLG3
(B) or negative controls (B9). C) Schematic of splicing products from a novel splicing reporter containing multimeric MS2 binding sites in exon 2 of the
pRHCglo minigene (MS2-vector); the unspliced pre-mRNA (1.91 kb), partially (928 bp), and fully spliced (190 bp) products are shown. D) RT-PCR
analysis to detect splicing products from the MS2 reporter RNA in HEK293 cells. In the presence of MS2-TBX3, a partially spliced mRNA is present
consisting of exons 1–3, but no introns (927 bp, lanes 3, 5). MS2-GFP (lane 4) and wild type TBX3 (lane 6) have no effect.
doi:10.1371/journal.pgen.1004247.g005
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Figure 6. Tbx3 binding partners associate with the Nfkb1 mRNA that is alternatively spliced in response to Tbx3, and a subset
require Tbx3 to bind this mRNA. A) RNA-IP with anti-Tbx3 on embryo lysates using antibodies against Tbx3 interacting proteins to test binding to
the Nfkb1 transcript which is differentially spliced in response to Tbx3 in mouse limb. Actin and Gapdh are negative controls. Note that not all Tbx3
interactors bind this mRNA. B) RIP/RT-PCR testing Tbx3 interactors for binding of the Nfkb1 mRNA in Tbx3 wild type (wt) and null (ko) murine
embryonic fibroblasts (MEFs). Ddx3 requires Tbx3 to bind the Nfkb1 mRNA (arrowhead) but hnrnpu does not. C) RT-PCR assay of splice variants in
control, Tbx3 and Ddx3 siRNA knockdown MEFs. Knockdown of Ddx3 results in the same alternative splicing of Nfkb1 exon 11 as Tbx3 knockdown,
whereas knockdown of hnrnpu decreases the total amount of Nfkb1 transcript but has no effect on exon 11 splicing. C9) Gapdh control RT-PCR.
doi:10.1371/journal.pgen.1004247.g006
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Numerous DNA binding transcription factors have now been
demonstrated not only to bind RNA [58] but to bind a similar motif
in RNA as in DNA, including some hnrnps [59,60,61,62,63].TBX3
may act as a docking molecule for assembly of RNA processing
complexes, as has been postulated for Smad proteins: in addition to
binding DNA of transcriptional targets, Smads bind to Smad binding
elements in pre-miRNAs (R-SBEs) conferring BMP/TGFb regula-
tion to pre-miRNA processing [59]. Additional investigation is
needed to determine how, and in what contexts, TBX3 exerts
different post-transcriptional effects: it may function as a docking
factor that directly binds pre-mRNAs, be recruited to pre-mRNAs
via association with RNA BPs, or influence the activity of SINE or
other regulatory elements.
The mutant Tbx3 proteins we tested for splicing activity in vitro
represent the spectrum of mutations seen in humans with UMS,
including the 1857delC frameshift [64]. Although we could not
examine the splicing activity of these mutations in vivo, the
minigene splicing assay (Figure 3) indicates that mutations that
truncate the protein 59 of the repressor domain dominantly
interfere with the ability of endogenous TBX3 to inhibit splicing,
while those that prevent DNA binding do not. The Nfkb1minigene
is alternately spliced to both shorter and longer isoforms in the
presence of Tbx3 mutants lacking the C-terminus (Figure 4). Based
on data in OMIM (http://www.omim.org/) and a review of the
literature, there are at least 10 human point mutations predicted to
cause premature termination and loss of the C-terminal repressor
domain. The human 1857 delC mutation is a missense mutation
in the C-terminus; while not an exact replicate of this mutation,
our exon7 missense mutation does produce a protein with an
altered C-terminus and abnormal splicing activity. Our observa-
tion that knockdown of TBX3 alters splicing has significant
implications that will require extensive further investigation since
the presumed mechanism for TBX3 loss of function mutations has
been haploinsufficiency of transcriptional repressor activity.
Furthermore, a subset of C-terminal human mutations encodes
truncated proteins that undergo increased rates of protein decay;
such mutations could thus disrupt splicing by multiple mecha-
nisms. In combination with our observations that AS regulation by
Tbx3 is context and mRNA dependent, the splicing functions of
Tbx3 provide additional complexity to regulation of gene
expression by Tbx3.
In conclusion, our study reveals that TBX3 is a splicing
regulator and that mutations seen in humans with UMS disrupt
this function. There is little genotype/phenotype correlation
Figure 7. TBX3 binds TBE-containing RNAs directly. A–E) EMSA assays of purified, MBP-conjugated Tbx3 with radiolabeled RNA probes whose
sequences are listed at bottom of panels. C–E) RNA probes derived from Nfkb1 intronic fragments (F1–F3). Black arrowheads: probe/protein complex;
clear arrowheads: unbound probe. F–H) Shift and supershift RNA EMSA assays of endogenous TBX3; radiolabeled probe sequences are listed below
panels. Probes were incubated +/2 HEK293 lysate, +/2 anti-TBX3 antibody, +/2 TBX3 knockdown. F) RNA probe containing GGUGU motifs. Probe/
protein complex (lane 5) supershifts with anti-TBX3 antibody (lanes 2, 3) and disappears with TBX3 knockdown (lane 6). TBX3+RNA complexes are
indicated by blue arrowheads, anti-Tbx3 antibody supershifted TBX3+RNA complexes are indicated by red arrowheads and unbound probe by black
arrowheads. Gray arrowhead indicates probe-protein complexes detected in the absence of TBX3 (lane 6). G) Mutation of the GGUGU to CCUGU
results in formation of probe/protein complexes (lane 2) does not supershift with anti-TBX3 antibody (lane 3) and unaffected by TBX3 knockdown
(lane 5). H) RNA probe containing AGGUGUG consensus TBE motif from Nfkb1 Fragment 3. Probe/protein complex (lanes 2, 3, 5, blue arrowhead)
supershifts with anti-TBX3 antibody (lanes 2, 3, red arrowheads) and decreases with TBX3 knockdown (lane 6). Gray arrowhead indicates probe-
protein complexes detected in the absence of TBX3 (lane 6). Probe incubated with no lysate (F–H, lanes 1) or anti-TBX3 antibody alone (F–H, lanes 4)
are additional negative controls. IgG negative control EMSAs are shown in Figure S5 G, H. I, J) Significantly over-represented sequence motifs
identified by MEME on genomic regions flanking statistically significant AS events contain the 59GGTG T-box core binding element.
doi:10.1371/journal.pgen.1004247.g007
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between and within UMS families, and phenotypes in mice are
extremely dosage sensitive. We propose that the pleiotropic effects
of TBX3 mutations result from disrupting at least two context-
specific molecular functions: transcriptional regulation and pre-
mRNA splicing. Dissecting the requirements for different TBX3
molecular functions in specific developmental and disease contexts
will improve our understanding of oncogenesis and UMS
pathogenesis. The splicing function of TBX3 may be a new target
for cancer treatment or in tissue regeneration efforts.
Materials and Methods
Cell culture and transfections
HEK293 cells were grown in DMEM with 10% FBS and pen/
strep. Plasmids and transfection procedures are detailed in
Supplemental Information in the file Text S1.
Immunoprecipitation
Dignam lysates were prepared from HEK293 cells or e10.5
mouse embryos. Immune complexes were subjected to SDS-PAGE
analysis followed by immunoblotting with specific antibodies.
Detailed procedures are in SI.
Enzymatic digestion of IP’d proteins and MS
IP’d proteins were separated by SDS-PAGE and in-gel digested
prior to analysis by MS as previously described [65,66]. GO
annotation analysis was performed with DAVID Bioinformatics
Resource as described in SI.
RNA interference
HEK-293 cells were transfected with control or TBX3-specific
siRNAs using lipofectamine 2000 (Invitrogen). RNA was extracted
48 hrs post-transfection and cDNA prepared with SuperScript III
Reverse Transcriptase (Invitrogen).
Retroviral transduction
High-titer retrovirus was produced by transfection of TBX3
shRNA retroviral construct along with gag/pol and VSVG
encoding plasmids into HEK293 EBNA cells. Stably integrated
colonies were selected and analyzed for TBX3 knockdown.
RNA IP
Lysates were IP’d with anti-TBX3 and R-IgG. RNA was
extracted with Tri reagent (Sigma), converted to cDNA. Primer
details and CLIP are described in SI.
RNA sequencing
Total RNA was isolated from pooled microdissected anterior
and posterior segments of e10.5 wild type and Tbx3 conditional
mutant forelimb buds using the miRNeasy Kit (Qiagen). Libraries
were prepared by the University of Utah Microarry Core and
single end sequencing reads obtained on an Illumina HiSeq2000.
Additional details and bioinformatic analyses are in SI.
Supporting Information
Figure S1 Dual-tagged pull down and immunoprecipitation
assays and RNA independence of TBX3 interactions. A–E)
Immunoblots of Ni-NTA eluate and anti-Myc immunoprecipita-
tion products from HEK293 cells expressing dually (His-Myc
tagged)-TBX3 to examine association with endogenous TBX3
interactors. The lanes labeled input contain the lysate prior to
application to the Ni-NTA column; those labeled Ni-NTA contain
the Ni-NTA eluate, whereas those labeled anti-Myc contain
dialyzed Ni-NTA eluate post IP with anti-Myc. The mouse IgG IP
is a negative control. Immunoblots were then probed with the
antibodies listed below the panels (IB). Endogenous hNRNPC1/
C2, DDX3, DDX17 and PABP1 are all bound, eluted with, and
coIP with His-Myc-TBX3. F–J) HEK293 lysates +/2 RNAse A
treatment were immunoprecipitated with the antibody listed at the
top of the panels (IP) and the antibodies used to probe the
immunoblot (IB) below. Only the interaction of FMRP with TBX3
(D) was affected by RNAse treatment. In all panels, the protein of
interest is noted by the red arrowhead; the ,50 kd band is IgG
from the IP (black arrowhead). In all panels, the protein of interest
is noted by the red arrowhead; the IgG band from the IP is labeled
with a black arrowhead. K) Coomassie Blue stained PAGE gels of
in vitro synthesized GST-DDX3, GST and MBP-GST. L) In vitro
GST pull down assays: GST or GST-DDX3 affinity columns were
incubated with. MBP-TBX3. Bound proteins were eluted,
subjected to SDS-PAGE followed by IB with anti-TBX3 antibody.
(TIF)
Figure S2 Tbx3 mutant proteins are produced after transfection
of expression plasmids and are efficiently immunoprecipitated. A)
Anti-Tbx3 immunoblot of HEK293 lysates post transfection of
Tbx3 constructs. Upper bands are full length proteins and the
lower bands are degradation products (confirmed by MS). B)
Immunoblot of IP’d HEK293 lysates. Upper bands are Tbx3
mutant proteins (red arrowheads show different size proteins);
,50 kd bands are IgG (black arrowhead). Anti-goat IgG serves as
a negative control for the IPs as the primary anti-Tbx3 IP
antibody employed for this experiment was raised in goat. C)
Production and IP of Tbx3DNLS protein in transfected HEK293
cells.
(TIF)
Figure S3 Tbx3 regulates alternative splicing of numerous
targets in vivo. A–C) Tbx3 regulates alternative splicing in mouse
limb buds in vivo. IGV screen shots comparing control anterior
(CA1, CA2), Tbx3;Prx1Cre mutant anterior (MA1, MA2) forelimb
bud RNA-Seq data for Nfkb1 exons 5,6 (A), Pus10 exons 7, 8 (B),
and Brca1 exon 8 (C). Red arrowheads indicate exons that are
differentially spliced in a Tbx3-dependent manner. A9–C9)
Schematics of splice variants and PCR primers used to detect
them and RT-PCR validating variants. Anterior, anterior
compartment; ctl1,control biologic replicate 1; mt1, mutant
biologic replicate 1; ctl2,control biologic replicate 2; mt2, mutant
biologic replicate 2.
(TIF)
Figure S4 RT-PCR testing of statistically significant versus
insignificant splicing events identified by RNA-seq. A) RT-PCR
testing of additional transcripts (listed at bottom of panels) from
statistically significant alternate splice events in the anterior
compartment (Tables S2, S3); all tested validated. B) RT-PCR
testing of genes with statistically insignificant alternate splice events
in the anterior compartment (Tables S2, S3); the events did not
validate (i.e. no difference in mutant and control). C) Actin mRNA
loading control. M, marker; Ctl, control; Mt, mutant.
(TIF)
Figure S5 Interaction of purified and endogenous TBX3 with
RNA probes. A–F) EMSAs of MBP-conjugated TBX3 with
radiolabeled RNA probe sequences listed at bottom of panels. red
arrowhead: probe/protein complex; black arrowheads: unbound
probe. G–H) Shift and supershift RNA EMSA assay of
endogenous TBX3 in HEK293 cell lysates; radiolabeled probe
sequences are listed below panels. Probes were incubated +/2
HEK293 lysate, +/2 anti-TBX3 antibody, and with the negative
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control antibody rabbit IgG (R-IgG). G) RNA probe containing
GGUGU motifs. Probe/protein complex (lane 2) supershifts with
Anti-TBX3 antibody (lanes 3) but not with R-IgG (lane 5).
TBX3+RNA complexes are indicated by blue arrowhead, anti-
Tbx3 antibody supershifted TBX3+RNA complexes are indicated
by red arrowhead and unbound probe by black arrowhead. H)
RNA probe containing AGGUGU motif from Nfkb1 Fragment 3.
Probe/protein complex (lanes 2, 3, 5) supershifts with Anti-TBX3
antibody (lane 2) but not with R-IgG (lane 5). TBX3+RNA
complexes are indicated by blue arrowhead, anti-Tbx3 antibody
supershifted TBX3+RNA complexes are indicated by red
arrowhead and unbound probe by black arrowhead.
(TIF)
Table S1 TBX3 interacting proteins meeting MS screen criteria.
(DOCX)
Table S2 Validation results of randomly selected alternatively
spliced target ordered by statistical significance.
(DOCX)
Table S3 RNA-Seq analysis of anterior limb compartment
control versus Tbx3 mutant transcripts. Data and significance are
provided for both expression fold change and splicing variants
detected.
(XLSX)
Table S4 Location of putative TBEs and MEME motifs for the
11 validated alternative splicing events in the anterior limb
compartment. Primary sequences of alternatively spliced exon and
1 kb of 59 and 39 flanking regions. Introns, exons, motifs and
conservation are as noted in the KEY.
(DOCX)
Text S1 Supplemental Methods and Figure Legends. This
supplement contains 2 sections: Supplemental Experimental
Procedures and Supplemental Information References.
(DOCX)
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